Savara (NASDAQ:SVRA) Sets New 52-Week Low Following Analyst Downgrade

Savara Inc (NASDAQ:SVRA) hit a new 52-week low on Thursday after HC Wainwright lowered their price target on the stock from $10.00 to $6.00. HC Wainwright currently has a buy rating on the stock. Savara traded as low as $3.24 and last traded at $3.32, with a volume of 128515 shares. The stock had previously closed at $3.25.

Several other analysts also recently weighed in on SVRA. Evercore ISI reissued an “in-line” rating and set a $5.00 target price (down previously from $7.00) on shares of Savara in a research report on Wednesday. JMP Securities reissued a “market outperform” rating and set a $9.00 price objective on shares of Savara in a report on Tuesday, October 1st. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat, Savara currently has a consensus rating of “Moderate Buy” and an average target price of $10.17.

Institutional Trading of Savara

Several institutional investors and hedge funds have recently bought and sold shares of the business. CANADA LIFE ASSURANCE Co purchased a new position in shares of Savara during the first quarter worth $35,000. Choreo LLC acquired a new stake in Savara during the 2nd quarter worth about $59,000. DRW Securities LLC purchased a new position in shares of Savara during the 2nd quarter valued at about $62,000. Principal Financial Group Inc. lifted its holdings in shares of Savara by 64.4% in the 2nd quarter. Principal Financial Group Inc. now owns 17,795 shares of the company’s stock valued at $72,000 after buying an additional 6,973 shares during the period. Finally, BNP Paribas Financial Markets lifted its holdings in shares of Savara by 258.9% in the 3rd quarter. BNP Paribas Financial Markets now owns 25,693 shares of the company’s stock valued at $109,000 after buying an additional 18,534 shares during the period. 87.93% of the stock is currently owned by institutional investors and hedge funds.

Savara Stock Up 0.6 %

The stock has a market cap of $538.25 million, a PE ratio of -7.79 and a beta of 1.02. The business has a 50 day moving average price of $3.93 and a 200 day moving average price of $4.21. The company has a quick ratio of 11.31, a current ratio of 11.31 and a debt-to-equity ratio of 0.26.

Savara (NASDAQ:SVRA) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.11) EPS for the quarter, hitting the consensus estimate of ($0.11). Equities research analysts expect that Savara Inc will post -0.44 EPS for the current fiscal year.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.